Skip to main navigation Skip to search Skip to main content

A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer

  • Khanh Do
  • , Liang Cao
  • , Zhigang Kang
  • , Baris Turkbey
  • , Maria L. Lindenberg
  • , Erin Larkins
  • , Beata Holkova
  • , Seth M. Steinberg
  • , Mark Raffeld
  • , Cody J. Peer
  • , William D. Figg
  • , Michelle Eugeni
  • , Paula Jacobs
  • , Peter Choyke
  • , John J. Wright
  • , James H. Doroshow
  • , Shivaani Kummar*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science